Mass Spectrometric Characterization of HIV-1 Reverse Transcriptase Interactions with Non-nucleoside Reverse Transcriptase Inhibitors. 2016

Ratsupa Thammaporn, and Kentaro Ishii, and Maho Yagi-Utsumi, and Susumu Uchiyama, and Supa Hannongbua, and Koichi Kato
Department of Chemistry, Faculty of Science, Kasetsart University.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) of human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) have been developed for the treatment of acquired immunodeficiency syndrome. HIV-1 RT binding to NNRTIs has been characterized by various biophysical techniques. However, these techniques are often hampered by the low water solubility of the inhibitors, such as the current promising diarylpyrimidine-based inhibitors rilpivirine and etravirine. Hence, a conventional and rapid method that requires small sample amounts is desirable for studying NNRTIs with low water solubility. Here we successfully applied a recently developed mass spectrometric technique under non-denaturing conditions to characterize the interactions between the heterodimeric HIV-1 RT enzyme and NNRTIs with different inhibitory activities. Our data demonstrate that mass spectrometry serves as a semi-quantitative indicator of NNRTI binding affinity for HIV-1 RT using low and small amounts of samples, offering a new high-throughput screening tool for identifying novel RT inhibitors as anti-HIV drugs.

UI MeSH Term Description Entries
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D000068696 Rilpivirine A diarylpyrimidine derivative and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 that is used in the treatment of HIV INFECTIONS. It is also used in combination with other ANTI-HIV AGENTS, since ANTIVIRAL DRUG RESISTANCE emerges rapidly when it is used alone. R278474,Rilpivirine HCl,Rilpivirine Hydrochloride,TMC 278,TMC-278,TMC278,278, TMC,HCl, Rilpivirine,Hydrochloride, Rilpivirine
D000480 Alkynes Hydrocarbons with at least one triple bond in the linear portion, of the general formula Cn-H2n-2. Acetylenic Compounds,Alkyne,Acetylenes
D013058 Mass Spectrometry An analytical method used in determining the identity of a chemical based on its mass using mass analyzers/mass spectrometers. Mass Spectroscopy,Spectrometry, Mass,Spectroscopy, Mass,Spectrum Analysis, Mass,Analysis, Mass Spectrum,Mass Spectrum Analysis,Analyses, Mass Spectrum,Mass Spectrum Analyses,Spectrum Analyses, Mass
D048588 Benzoxazines OXAZINES with a fused BENZENE ring. Benzoxazine,Benzoxazinoid,Benzoxazinone,Benzoxazinones,Benzoxazinoids
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse

Related Publications

Ratsupa Thammaporn, and Kentaro Ishii, and Maho Yagi-Utsumi, and Susumu Uchiyama, and Supa Hannongbua, and Koichi Kato
February 2006, Current opinion in investigational drugs (London, England : 2000),
Ratsupa Thammaporn, and Kentaro Ishii, and Maho Yagi-Utsumi, and Susumu Uchiyama, and Supa Hannongbua, and Koichi Kato
December 2013, Future medicinal chemistry,
Ratsupa Thammaporn, and Kentaro Ishii, and Maho Yagi-Utsumi, and Susumu Uchiyama, and Supa Hannongbua, and Koichi Kato
October 2015, Scientific reports,
Ratsupa Thammaporn, and Kentaro Ishii, and Maho Yagi-Utsumi, and Susumu Uchiyama, and Supa Hannongbua, and Koichi Kato
February 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy,
Ratsupa Thammaporn, and Kentaro Ishii, and Maho Yagi-Utsumi, and Susumu Uchiyama, and Supa Hannongbua, and Koichi Kato
September 2006, Bioorganic & medicinal chemistry,
Ratsupa Thammaporn, and Kentaro Ishii, and Maho Yagi-Utsumi, and Susumu Uchiyama, and Supa Hannongbua, and Koichi Kato
June 2003, AIDS (London, England),
Ratsupa Thammaporn, and Kentaro Ishii, and Maho Yagi-Utsumi, and Susumu Uchiyama, and Supa Hannongbua, and Koichi Kato
October 2005, Expert opinion on drug metabolism & toxicology,
Ratsupa Thammaporn, and Kentaro Ishii, and Maho Yagi-Utsumi, and Susumu Uchiyama, and Supa Hannongbua, and Koichi Kato
February 2016, Molecules (Basel, Switzerland),
Ratsupa Thammaporn, and Kentaro Ishii, and Maho Yagi-Utsumi, and Susumu Uchiyama, and Supa Hannongbua, and Koichi Kato
February 2004, Journal of medicinal chemistry,
Ratsupa Thammaporn, and Kentaro Ishii, and Maho Yagi-Utsumi, and Susumu Uchiyama, and Supa Hannongbua, and Koichi Kato
February 2019, The journal of physical chemistry. B,
Copied contents to your clipboard!